Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
esophageal cancer
Pharma
FDA challenges broad use of PD-1 drugs in stomach cancer
The FDA is considering a class-wide action against PD-1 inhibitors in stomach cancer and esophageal cancer based on findings from multiple trials.
Angus Liu
Sep 24, 2024 2:30pm
With ODAC, FDA weighs limiting PD-1 drugs in stomach cancer
Aug 22, 2024 3:28pm
Castle Biosciences fortifies esophageal cancer awareness efforts
Apr 11, 2024 12:30pm
BeiGene finally snags FDA approval for PD-1 drug Tevimbra
Mar 15, 2024 8:39am
Novartis returns PD-1 to BeiGene in another cancer drug divorce
Sep 19, 2023 9:10am
Novartis, BeiGene's PD-1 hits FDA setback
Jul 14, 2022 10:30am
